logo
‘Dead' thrusters revived to help Voyager 1 through a communications pause

‘Dead' thrusters revived to help Voyager 1 through a communications pause

Yahoo15-05-2025

Sign up for CNN's Wonder Theory science newsletter. Explore the universe with news on fascinating discoveries, scientific advancements and more.
Engineers at NASA say they have successfully revived thrusters aboard Voyager 1, the farthest spacecraft from our planet, in the nick of time before a planned communications blackout.
A side effect of upgrades to an Earth-based antenna that sends commands to Voyager 1 and its twin, Voyager 2, the communications pause could have occurred when the probe faced a critical issue — thruster failure — leaving the space agency without a way to save the historic mission. The new fix to the vehicle's original roll thrusters, out of action since 2004, could help keep the veteran spacecraft operating until it's able to contact home again next year.
Voyager 1, launched in September 1977, uses more than one set of thrusters to function properly. Primary thrusters carefully orient the spacecraft so it can keep its antenna pointed at Earth. This ensures that the probe can send back data it collects from its unique perspective 15.5 billion miles (25 billion kilometers) away in interstellar space, as well as receive commands sent by the Voyager team.
Within the primary set are additional thrusters that control the spacecraft's roll, which enables Voyager 1 to remain pointed at a guide star so it can remain oriented in space.
If Voyager can't control its roll motion, the mission could be threatened.
But as the thrusters fire, tiny amounts of propellant residue have built up over time. So far, engineers have managed to avoid clogging by commanding Voyager 1 to cycle between its original and backup thrusters for orientation, as well as a set of thrusters that were used to change the spacecraft's trajectory during planetary flybys in the 1980s. The trajectory thrusters, however, do nothing to contribute to the spacecraft's roll.
Voyager 1's original roll thrusters stopped working more than two decades ago after power was lost in two internal heaters, which means the spacecraft has been relying on the backup roll thrusters to remain pointed at a guide star ever since.
'I think at that time, the team was OK with accepting that the primary roll thrusters didn't work, because they had a perfectly good backup,' said Kareem Badaruddin, Voyager mission manager at NASA's Jet Propulsion Laboratory in Pasadena, California, in a statement. 'And, frankly, they probably didn't think the Voyagers were going to keep going for another 20 years.'
Now, Voyager 1 engineers are concerned that clogging from the residue could cause the spacecraft's backup roll thrusters to stop working as soon as this fall — and they had to get creative, as well as take risks, to revive the long-defunct primary roll thrusters.
When the heaters on the primary roll thrusters failed in 2004, engineers thought they couldn't be fixed. But with the threat posed by clogging looming, the team returned to the drawing board to see what had gone wrong.
Engineers considered the possibility that a disturbance in the circuits controlling the power supply to the heaters flipped a switch to the wrong position — and flipping it to the original position might restart the heaters, and in turn, the primary roll thrusters.
But it wasn't a straightforward solution for a probe that's operating so far away. The spacecraft is currently beyond the heliosphere, the sun's bubble of magnetic fields and particles that extends well beyond the orbit of Pluto.
The mission team had to take a risk by switching Voyager 1 to its primary roll thrusters and turning them on before attempting to fix and restart the heaters. The heaters could only function if the thrusters are also switched on.
If Voyager 1 drifted too far from its guide star, the spacecraft's programming would trigger the roll thrusters to fire — but if the heaters weren't turned on yet at that moment, the automatic sequence could have triggered a small explosion.
In addition to the risk, the team, which began its work earlier this year, was facing a time constraint. A giant Earth-based antenna in Canberra, Australia, went offline May 4 for upgrades that will be ongoing until February 2026. NASA's Deep Space Network enables the agency to communicate with all of its spacecraft — but its Canberra antenna is the only one with enough signal strength to send commands to the Voyager probes.
'These antenna upgrades are important for future crewed lunar landings, and they also increase communications capacity for our science missions in deep space, some of which are building on the discoveries Voyager made,' said Suzanne Dodd, Voyager project manager and director of the Interplanetary Network at JPL, which manages the Deep Space Network for NASA, in a statement. 'We've been through downtime like this before, so we're just preparing as much as we can.'
While the antenna will briefly operate in August and December, the mission team members wanted to command Voyager 1 to test its long-dormant thrusters before they could no longer communicate with the spacecraft. This way, if they need to turn on the thrusters in August, the team would know whether that was a viable option.
On March 20, the team waited to see the results return from Voyager 1 after sending a command to the probe the day before to activate the thrusters and heaters. It takes more than 23 hours for data to travel back from Voyager 1 to Earth due to the sheer distance between the two.
Had the test failed, Voyager 1 may have already been at risk. But the team watched the data stream in, showing the temperature of the thruster heaters rising dramatically, and knew it had worked.
'It was such a glorious moment. Team morale was very high that day,' said Todd Barber, the mission's propulsion lead at JPL, in a statement. 'These thrusters were considered dead. And that was a legitimate conclusion. It's just that one of our engineers had this insight that maybe there was this other possible cause and it was fixable. It was yet another miracle save for Voyager.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Astronomers discover ultrapowerful black hole jet as bright as 10 trillion suns lit by Big Bang's afterglow
Astronomers discover ultrapowerful black hole jet as bright as 10 trillion suns lit by Big Bang's afterglow

Yahoo

time34 minutes ago

  • Yahoo

Astronomers discover ultrapowerful black hole jet as bright as 10 trillion suns lit by Big Bang's afterglow

When you buy through links on our articles, Future and its syndication partners may earn a commission. Astronomers have discovered extraordinarily powerful X-ray jets blasting from two supermassive black holes that are so ancient that the jets shine in the afterglow of the Big Bang. "They are transforming the first light of the universe into high-energy jets," Jaya Maithil, a postdoctoral research fellow at the Harvard and Smithsonian Center for Astrophysics, told reporters Monday (June 9) at the 246th meeting of the American Astronomical Society in Anchorage, Alaska. Using data from NASA's Chandra X-Ray Observatory and the Karl G. Jansky Very Large Array (VLA), Maithil and her team found that each jet spans a whopping 300,000 light-years — nearly three times the diameter of our Milky Way galaxy. Each jet emerges from an actively feeding supermassive black hole, known as a quasar, located about 11.6 billion and 11.7 billion light-years away. The researchers observed these immense structures as they appeared when the universe was just 3 billion years old, during a period when galaxies and their central black holes were growing at breakneck speed. "These quasars are like cosmic time capsules," Maithil said. "If we understand them, we can understand how they were impacting the growth of their galaxy and the environment in which they resided." One of the newfound jets, from a quasar known as J1610+1811, is visible in the Chandra image above. A slender, faint purple line extends from the quasar's brilliant white core toward the upper right, ending in a small, bright blob. A second, dimmer jet appears to shoot in the opposite direction, downward and to the left. "It's like looking for candlelight in close vicinity to a flashlight that's blazing toward us," Maithil said. Related: Hungry black hole shoots out bright X-ray jet 60,000 times hotter than the sun What makes these jets particularly noteworthy is that they remain visible across billions of light-years. In a paper accepted for publication in The Astrophysical Journal, Maithil and her team suggested that the jets shine in X-rays thanks to interactions with the cosmic microwave background (CMB) — the faint relic radiation from the Big Bang left over after the universe cooled enough for starlight to travel freely for the first time, marking the end of the "cosmic dark ages." Back when these jets formed, the CMB was far denser than it is today, filling space with a sea of low-energy photons. As electrons in the jets raced outward at near light speed, they slammed into these CMB photons, boosting them into the X-ray range detectable by Chandra, according to the new study. RELATED STORIES —Brightest quasar ever seen is powered by black hole that eats a 'sun a day' —How black-hole-powered quasars killed off neighboring galaxies in the early universe —Distant 'quasar tsunamis' are ripping their own galaxies apart This process makes them visible across cosmic gulfs, despite their proximity to the quasars' dazzling cores, the researchers said. The jet from J1610+1811 clocks in at 92% to 98% light, carrying about half as much energy as all the light emitted by matter spiraling into the black hole — a staggering output equivalent to that from 10 trillion suns, the new study found. The second quasar, J1405+0415, located 11.7 billion light-years from Earth, features a jet just as powerful. By combining Chandra's X-ray and VLA's radio data, the researchers calculated that particles in the J1405+0415 jet are traveling at 95% to 99% the speed of light. "We're finding that some black holes may carry a bigger punch at this stage in the universe than we thought," Maithil said in a statement.

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Business Upturn

timean hour ago

  • Business Upturn

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, demonstrating the potential of lonvo-z to become the first one-time therapy for most HAE patients Lonvo-z was well tolerated and continues to demonstrate a favorable safety profile The global Phase 3 HAELO trial of lonvo-z has concluded screening ahead of schedule with more than half screened from U.S. sites; Intellia to provide an update on enrollment in the future CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom. 'Today's results underscore the promising potential of Intellia's approach to gene editing therapy – a one-time treatment that was well tolerated and offered a highly differentiated, durable effect for patients suffering from a serious disease,' said Intellia President and Chief Executive Officer John Leonard, M.D. 'Seeing all 10 patients in the Phase 1 portion of this study free from both HAE attacks and chronic therapy at nearly two years of median follow-up is incredibly encouraging. These data fuel our optimism for the outcomes of our ongoing Phase 3 HAELO study, which we expect to report in the first half of 2026, and highlight the strong value we believe it will offer patients, physicians and payers.' 'People living with HAE often report a reduced quality of life because they worry about the likelihood of their next attack, either because they still experience attacks or are reminded of it by their use of chronic therapy,' said Dr. Joshua Jacobs, Medical Director, Allergy and Asthma Clinical Research, Inc. 'Based on the data, it is reasonable to expect lonvo-z could offer patients the potential to be free from both physical HAE attacks and the burden of managing chronic HAE treatment.' In the Phase 1 portion of the study, a one-time dose of 25 mg (N=3), 50 mg (N=4) or 75 mg (N=3) of lonvo-z was administered via intravenous infusion and plasma kallikrein protein levels were measured along with HAE attacks. At the time of the February 12 data cutoff, patients were attack-free and treatment-free for a median of nearly two years. With up to three years of follow-up, a single dose of lonvo-z led to a mean reduction in monthly HAE attack rate of 98% over the study period, compared to pre-treatment baseline. For all 10 patients, deep, dose-dependent and durable reductions in plasma kallikrein protein continued to be observed through the latest assessment. Safety Across all three dose levels, lonvo-z has been well tolerated and continues to demonstrate a favorable safety profile consistent with earlier data presented at EAACI in 2024. The most frequent adverse events during the study period were infusion-related reactions (IRRs). IRRs were mostly Grade 1 and resolved with all patients receiving the full dose. With up to 3 years of follow-up, no treatment-emergent serious adverse events were observed, and no treatment-related adverse events were observed during the period following 28 days after dosing. Clinical Development Plans Intellia's global Phase 3, randomized, double-blind, placebo-controlled HAELO trial is ongoing to assess the safety and efficacy of lonvo-z at the 50 mg dosage. The Company announced today the HAELO trial has successfully completed screening ahead of schedule, with over half of the patients being screened in the United States. The study is no longer recruiting and Intellia will provide an update on enrollment in the future. New and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study is planned to be presented in the second half of 2025. Intellia expects to submit a biologics license application (BLA) in 2026 to support the Company's plans for a U.S. launch in 2027. For more information on HAELO (NCT06634420), please visit About the Lonvoguran Ziclumeran (lonvo-z, also known as NTLA-2002) Clinical Program Intellia's ongoing Phase 1/2 study is evaluating the safety and efficacy of lonvo-z in adults with Type I or Type II hereditary angioedema (HAE). The Phase 1 portion of the study is an international, open-label study designed to identify the dose level of lonvo-z selected for further evaluation in the Phase 2 portion of the study. Enrollment in both portions of the Phase 1/2 study is complete. Intellia dosed the first patient in the global Phase 3, randomized, double-blind, placebo-controlled HAELO trial in January of 2025. Visit (NCT05120830) for more details. About Lonvo-z Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an investigational in vivo CRISPR-based gene editing therapy designed to prevent HAE attacks by inactivating the kallikrein B1 ( KLKB1 ) gene, which encodes for prekallikrein, the kallikrein precursor protein. Interim Phase 1/2 clinical data showed dramatic reductions in attack rate, as well as consistent, deep and durable reductions in kallikrein levels. Lonvo-z has received five notable regulatory designations, including Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission. About Intellia Therapeutics Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia's deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at and follow us @intelliatx. Forward-Looking Statements This press release contains 'forward-looking statements' of Intellia Therapeutics, Inc. ('Intellia' or the 'Company') within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and expectations concerning: the safety, efficacy, success and advancement of its clinical programs for lonvoguran ziclumeran or 'lonvo-z' (also known as NTLA-2002) for hereditary angioedema ('HAE'), including the ability to successfully complete its global Phase 3 HAELO study; its expectation to present additional data regarding lonvo-z, including reporting outcomes of the Phase 3 HAELO study in the first half of 2026 and presenting new and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study of lonvo-z in the second half of 2025; and its expectation to be able to support a biologics license application for lonvo-z for the treatment of HAE by 2026 for a U.S. launch in 2027. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to Intellia's relationship with third parties, including its contract manufacturers, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia's relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies' evaluation of regulatory filings and other information related to our product candidates, including lonvo-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials, including our ability to complete the Phase 3 HAELO study for HAE; the risk that any one or more of Intellia's product candidates, including lonvo-z, will not be successfully developed and commercialized; and the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia's other product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia's actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in Intellia's most recent annual report of Form 10-K and quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Intellia's other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law. Intellia Contacts: Investors:Brittany ChavesSenior Manager, Investor Relations [email protected]

US government uses UFOs as cover to ‘hide a lot of things': ex-NASA official
US government uses UFOs as cover to ‘hide a lot of things': ex-NASA official

New York Post

time5 hours ago

  • New York Post

US government uses UFOs as cover to ‘hide a lot of things': ex-NASA official

In an era captivated by unidentified flying objects (UFOs) and government conspiracies, one former NASA official is cutting through the noise and casting doubt on aliens coming to Earth. Joseph Gutheinz, a retired senior special agent with NASA's Office of Inspector General and current criminal defense attorney, said it's time to apply science, not speculation, to the debate. 'Prove it. Honestly, prove it,' he said to those who believe in the presence of UFOs on Earth. 'They've been claiming that there have been UFOs since the 1940s. And, you know, Area 51 supposedly houses UFOs,' he told Fox News Digital. 'Have someone go in, look at Area 51.' Gutheinz said that during his work with the NASA Office of Inspector General, he would regularly get calls from individuals who believed they were abducted, or had a chip in their brain from aliens. 4 Joseph Gutheinz, a former NASA agent, is casting doubt on aliens coming to Earth. Fox News 4 Gutheinz said that during his work with the NASA Office of Inspector General, he would get calls from people who thought they were abducted, or had a chip in their brain from aliens. AP 'What I used to tell my students was the possibility of anybody coming from another world to visit us was beyond unlikely,' he said. 'And what I would tell the people that would call me up with these tales about being visited by aliens, see a psychiatrist.' Citing astronomical distances and scientific understanding of the solar system, Gutheinz explained the improbability of any extraterrestrial visitors reaching Earth. 'There are up to 400 billion stars in the Milky Way. There are maybe one to two trillion galaxies in the universe. But the reality is this, the closest solar system is Alpha Centauri. Alpha Centauri A, B, and Proxima Centauri are the closest stars,' he said. 4 A UFO variety was photographed when it hovered for fifteen minutes near Holloman Air Development Center in New Mexico. Bettmann Archive 'The bottom line is that it's 4.4 light years away, or 25 trillion miles away. And if somebody started flying to Proxima and Satori, or the other way around, it would take them over 70,000 years to get there,' he said. 'Nobody is visiting us from another world, likely.' He pointed to moons like Europa, Ganymede, Titan, and Triton as the only plausible places for primitive life in our solar system. 'If there is life on any of those moons, it's possible. Again, it is primitive, it is microorganisms, it's nothing that's going to visit us in a flying saucer.' 4 Razor wire and security cameras at the entrance to Area 51, a secretive U.S. military base believed by UFO enthusiasts to hold government secrets about extraterrestrials. REUTERS When asked whether such sightings could be explained as natural or spiritual phenomena, he suggested that it could be government testing. 'If you're seeing something up there, and it's real, it's coming from the Chinese or the Russians or your next-door neighbor flying around with their drone,' he said. Historical military secrecy, Gutheinz suggested, may have played a major role in fostering the UFO myths. 'I believe early on in the 1940s when all these UFO stories started coming up, it was because the military was probably testing some aircraft, and they didn't want the Russians to know about it,' he said. 'And so, if the UFO cover worked, and I would not be surprised if there are some people in the military and the government that played along with that in order to conceal our stealth technology, that is really remarkable, and they just don't want to share that with other countries.' 'The bottom line is, I think that we use the UFO cover to hide a lot of things.' Fox News Digital has reached out to NASA for comment.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store